恒瑞医药(600276.SH)：SHR-4610注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative anti-tumor drug SHR-4610 injection, which shows promising anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] Company Summary - The company’s subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., is responsible for the clinical trial of SHR-4610 injection [1] - The total research and development investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1] Industry Summary - The approval of SHR-4610 injection for clinical trials indicates a positive development in the field of innovative anti-tumor therapies, potentially enhancing the company's position in the pharmaceutical industry [1]